Geovax Labs, INC 8-K filings

GeoVax Labs reports Q2 2026 financial results, highlighting progress on its GEO-MVA vaccine candidate and Gedeptin immuno-oncology program, with plans for a pivotal immunobridging study in Q4 2026.

GeoVax Labs received a notice from Nasdaq indicating non-compliance with the minimum stockholders equity requirement, with a plan to regain compliance due by August 21, 2026.

GeoVax Labs, Inc. reported on its annual meeting held June 17, 2026, where stockholders elected directors and approved several warrant exercise proposals.

GeoVax Labs announced a $3 million private placement financing, issuing common stock and warrants to institutional investors.

GeoVax Labs reported first quarter 2026 financial results, highlighting progress on its GEO-MVA mpox vaccine Phase 3 trial and continued development of its Gedeptin immuno-oncology therapy.

GeoVax Labs Inc. announced a warrant inducement transaction to encourage holders of existing warrants to exercise them for cash, resulting in the issuance of new warrants.

GeoVax Labs announced 2025 year-end financial results, reporting a net loss of $21.5 million, and provided a business update highlighting the upcoming Phase 3 trial for its GEO-MVA mpox/smallpox vaccine.

GeoVax Labs, Inc. secured approximately $863,000 in gross proceeds by inducing existing warrant holders to exercise their warrants at a reduced price, issuing new warrants in return.

GeoVax Labs, Inc. has implemented a 1-for-25 reverse stock split, effective January 9, 2026, to consolidate its common stock.

GeoVax Labs, Inc. completed a public offering of common units and warrants, raising approximately $3.2 million in gross proceeds for working capital and general corporate purposes.

GeoVax Labs' stockholders approved the issuance of shares for warrant exercises and a reverse stock split at a special meeting held on November 26, 2025.

GeoVax Labs reports Q3 2025 financial results, highlighting accelerated Mpox vaccine development, strong COVID-19 vaccine clinical data, and expansion of oncology programs, despite an increased net loss and BARDA contract termination.

GeoVax Labs, Inc. announced the closing of a $2.5 million registered direct offering and concurrent private placement of warrants to fund its product candidates and operations.

GeoVax Labs, Inc. received a deficiency letter from Nasdaq for failing to meet the minimum $1.00 bid price requirement, initiating a 180-day compliance period.

GeoVax Labs reports Q2 2025 financial results, highlighting favorable European regulatory guidance for GEO-MVA, strong immune responses for GEO-CM04S1, and progress for Gedeptin, despite an increased net loss and BARDA contract termination.

GeoVax Labs, Inc. has successfully closed a public offering, raising approximately $6 million in gross proceeds through the sale of common units, each comprising common stock and warrants.

GeoVax Labs, Inc. announced that its stockholders approved all proposals at the annual meeting held on June 5, 2025, including the election of seven directors, the 2025 Stock Incentive Plan, and a warrant exercise proposal.

GeoVax Labs announces its Q1 2025 financial results, highlighting progress in its COVID-19 vaccine program and upcoming clinical trials for Mpox/Smallpox and head and neck cancer treatments.

GeoVax Labs received notification from Advanced Technology International (ATI) to halt work on its GEO-CM04S1 COVID-19 vaccine Phase 2b clinical trial due to BARDA's decision to terminate the contract for convenience.

GeoVax Labs, Inc. announced its 2024 year-end financial results and provided a business update, highlighting clinical trial progress and operational developments.

GeoVax Labs, Inc. has entered into a securities purchase agreement for a $4.5 million registered direct offering with a healthcare-focused institutional investor.

GeoVax Labs stockholders approved proposals related to the issuance of common stock upon the exercise of warrants issued in connection with private placement offerings from May and July 2024.

GeoVax Labs adjourned its special stockholder meeting due to insufficient quorum and has rescheduled it for January 22, 2025.

GeoVax Labs has successfully regained compliance with Nasdaq's minimum stockholders' equity requirement, resolving a prior delisting concern.

GeoVax Labs announced its third quarter 2024 financial results, highlighting progress in its COVID-19 vaccine and other clinical programs, including a significant BARDA contract and advancements in Mpox and head and neck cancer therapies.

GeoVax Labs adjourned its special stockholder meeting due to insufficient quorum and has rescheduled it for November 12, 2024.

GeoVax Labs has increased the maximum aggregate offering price of its shares under a sales agreement to $30 million.

GeoVax Labs adjourned its special stockholder meeting due to insufficient quorum and has rescheduled it for October 16, 2024.

GeoVax Labs has entered into a sales agreement with A.G.P./Alliance Global Partners to potentially sell up to $4.48 million of its common stock through an at-the-market offering.

GeoVax Labs adjourned its Special Stockholder Meeting on September 17, 2024, due to insufficient quorum and has rescheduled it for October 1, 2024.